Patient Access to Urgent-Use Pharmacy Compounding Act of 2021

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Client expense: $410,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Client expense: $410,000 · Firm income: Not reported

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $120,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services; Draft legislation, the PBM Transparency, Accountability, and Reform Act

Client expense: $320,000 · Firm income: Not reported

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Medicare Physician Payment Reform Issues Medicare sequestration cuts Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act S. 4333, the CLEAR Act S. 4348, Food and Drug Administration Safety & Landmark Advancements (FDASLA) Act

Client expense: $295,000 · Firm income: Not reported

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2023 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2023 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Client expense: $570,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. (S. 610) Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021 Support H.R. 8437, the Improving Seniors Timely Access to Care Act of 2022 Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes. Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Support H.R. 7995, GOLD CARD Act of 2022 Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 8800, Supporting Medicare Providers Act of 2022 Advocate against H.R 6708, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program.

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $130,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services

Client expense: $400,000 · Firm income: Not reported

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.

Client expense: $360,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. (S. 610) Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 6020, the Supporting Medicare Providers Act Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022). Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes. Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act Support H.R. 7995, GOLD CARD Act of 2022 Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, extend the congressionally-enacted 3% temporary increase in the Medicare Physician Fee Schedule (MPFS) conversion factor to avoid cuts associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Advocate against H.R 6708, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program.

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $130,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Implementation Issues Medicare Physician Payment Issues HR 315, Medicare Sequester COVID Moratorium Act Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Vision Services Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act Coronavirus Pandemic Relief Measures HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act S. 4333, the CLEAR Act S. 4348, Food and Drug Administration Safety & Landmark Advancements (FDASLA) Act

Client expense: $250,000 · Firm income: Not reported

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2023 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2023 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services

Client expense: $460,000 · Firm income: Not reported

H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $140,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Lobby members of Congress regarding access problems to iPLEDGE/REMS program for isotretinoin.

Client expense: $470,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. (S. 610) Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173, Improving Seniors Timely Access to Care Act Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for a study on skin cancer in minority populations and communities to be included in the FY2022 Labor, Health and Human Services, Education and Related Agencies Appropriations bill and FY2022 Omnibus (H.R. 4502/H.R. 2471) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 6020, the Supporting Medicare Providers Act Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin. Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 111-148 Affordable Care Act, modifications Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Implementation Issues Medicare Physician Payment Issues HR 315, Medicare Sequester COVID Moratorium Act Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Vision Services Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act Coronavirus Pandemic Relief Measures HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act

Client expense: $260,000 · Firm income: Not reported

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; Draft legislation, Prescription Information Modernization Act;

Client expense: $2,010,000 · Firm income: Not reported

H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act

Client expense: $2,100,000 · Firm income: Not reported

H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit.

Client expense: $35,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 111-148 Affordable Care Act, modifications P.L. 113-54, Drug Quality & Security Act, all sections Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Implementation Issues Medicare Physician Payment Issues HR 315, Medicare Sequester COVID Moratorium Act Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Proposed MFN Drug Pricing Demo Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173/S 3018, the Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Vision Services Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act Coronavirus Pandemic Relief Measures HR 1799, the PPP Extension Act HR 1319, the American Rescue Plan Act of 2021 HR 869/S 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act HR 6020, the Supporting Medicare Providers Act of 2021 HR 5376, the Build Back Better Act HR 6000, Cures 2.0 Act

Client expense: $280,000 · Firm income: Not reported

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Lobby regarding access problems to iPLEDGE/REMS program for isotretinoin.

Client expense: $440,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer. Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. (S. 610) Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173, Improving Seniors Timely Access to Care Act Support H.R. 1554, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for a study on skin cancer in minority populations and communities to be included in the FY2022 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 4502) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2. Support H.R. 6020, the Supporting Medicare Providers Act Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act Lobby regarding access problems to iPLEDGE/REMS program for isotretinoin.

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2022 Appropriations HR3662, the Patient Access to Urgent Use Compounded Medication Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act

Client expense: $430,000 · Firm income: Not reported

Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act

Client expense: $390,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2163/S. 464, Safe Step Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 153, Protecting Consumer Access to Generic Drugs Act Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislation. Support H.R. 1677/S. 620, the KEEP Telehealth Options Act. Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021 Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667). Support H.R. 3173, Improving Seniors Timely Access to Care Act Support H.R. 1554, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256) Advocate for a study on skin cancer in minority populations and communities to be included in the FY2022 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 4502) Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Support H.R. 5054, Keep Physicians Serving Patients Act Advocate to support extension of moratorium on 2% Medicare sequester as well as waiving PAYGO and mitigating anticipated additional 4% cuts to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2.

Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, Interstate shipment of compounded prescriptions, H.R. 3662, the Patient Access to Urgent Use Pharmacy Compounding Act of 2021.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.

Client expense: $110,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

P.L. 111-148 Affordable Care Act, modifications P.L. 113-54, Drug Quality & Security Act, all sections Prior authorization utilization policies Medicare Access and CHIP Reauthorization Act (P.L. 114-10) Implementation Issues Medicare Physician Payment Issues HR 315, Medicare Sequester COVID Moratorium Act Drug Pricing and Shortages Issues Medicare Part B Drug Price Issues Proposed MFN Drug Pricing Demo Expansion of Telehealth Services Vision Research Funding Implementation of No Surprise Act HR 3173, Improving Seniors' Timely Access to Care Act HR 2163/S 464, Safe Step Act HR 1916/S 754, Ensuring Lasting Smiles Act Medicare Coverage for Vision Services Medicare Coverage for Low Vision Devices HR 4187, the Medicare Vision Act Coronavirus Pandemic Relief Measures HR 1799, the PPP Extension Act HR 1319, the American Rescue Plan Act of 2021 HR 869, S. 289, Research Investment to Spark the Economy (RISE) Act HR 366, Protecting Access to Post-COVID 19 Telehealth Act HR3662, Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 HR 3353, the Contact Lens Prescription Verification Modernization Act HR4122, Resident Education Deferred Interest (REDI) Act

Client expense: $220,000 · Firm income: Not reported